Rates of Antipsychotic Drug Prescribing Among People Living With Dementia During the COVID-19 Pandemic.

Importance Concerns have been raised that the use of antipsychotic medication for people living with dementia might have increased during the COVID-19 pandemic. Objective To examine multinational trends in antipsychotic drug prescribing for people living with dementia before and during the COVID-19 pandemic. Design, Setting, and Participants This multinational network cohort study used electronic health records and claims data from 8 databases in 6 countries (France, Germany, Italy, South Korea, the UK, and the US) for individuals aged 65 years or older between January 1, 2016, and November 30, 2021. Two databases each were included for South Korea and the US. Exposures The introduction of population-wide COVID-19 restrictions from April 2020 to the latest available date of each database. Main Outcomes and Measures The main outcomes were yearly and monthly incidence of dementia diagnosis and prevalence of people living with dementia who were prescribed antipsychotic drugs in each database. Interrupted time series analyses were used to quantify changes in prescribing rates before and after the introduction of population-wide COVID-19 restrictions. Results A total of 857 238 people with dementia aged 65 years or older (58.0% female) were identified in 2016. Reductions in the incidence of dementia were observed in 7 databases in the early phase of the pandemic (April, May, and June 2020), with the most pronounced reduction observed in 1 of the 2 US databases (rate ratio [RR], 0.30; 95% CI, 0.27-0.32); reductions were also observed in the total number of people with dementia prescribed antipsychotic drugs in France, Italy, South Korea, the UK, and the US. Rates of antipsychotic drug prescribing for people with dementia increased in 6 databases representing all countries. Compared with the corresponding month in 2019, the most pronounced increase in 2020 was observed in May in South Korea (Kangwon National University database) (RR, 2.11; 95% CI, 1.47-3.02) and June in the UK (RR, 1.96; 95% CI, 1.24-3.09). The rates of antipsychotic drug prescribing in these 6 databases remained high in 2021. Interrupted time series analyses revealed immediate increases in the prescribing rate in Italy (RR, 1.31; 95% CI, 1.08-1.58) and in the US Medicare database (RR, 1.43; 95% CI, 1.20-1.71) after the introduction of COVID-19 restrictions. Conclusions and Relevance This cohort study found converging evidence that the rate of antipsychotic drug prescribing to people with dementia increased in the initial months of the COVID-19 pandemic in the 6 countries studied and did not decrease to prepandemic levels after the acute phase of the pandemic had ended. These findings suggest that the pandemic disrupted the care of people living with dementia and that the development of intervention strategies is needed to ensure the quality of care.

[1]  M. Smalbrugge,et al.  The course of neuropsychiatric symptoms and psychotropic drug use in Dutch nursing home patients with dementia during the first wave of COVID‐19: A longitudinal cohort study , 2022, International journal of geriatric psychiatry.

[2]  T. Taverner,et al.  Decreased renal function is associated with incident dementia: An IMRD‐THIN retrospective cohort study in the UK , 2022, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[3]  I. Vahia,et al.  Impact of COVID-19 restrictions on behavioural and psychological symptoms in home-dwelling people with dementia: a prospective cohort study (PAN.DEM) , 2022, BMJ Open.

[4]  H. Oh,et al.  Containment, Health, and Social Policies in the Time of COVID-19 - Patterns and Determinants of Initial Reponses from Spring 2020 Across 120 Countries. , 2021, Health policy and planning.

[5]  M. Suchard,et al.  Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study , 2021, BMJ.

[6]  Andrew E. Williams,et al.  Thirty-Day Outcomes of Children and Adolescents With COVID-19: An International Experience , 2021, Pediatrics.

[7]  K. Verhamme,et al.  Background rates of five thrombosis with thrombocytopenia syndromes of special interest for COVID-19 vaccine safety surveillance: incidence between 2017 and 2019 and patient profiles from 20.6 million people in six European countries , 2021, medRxiv.

[8]  D. Madigan,et al.  Drawing Reproducible Conclusions from Observational Clinical Data with OHDSI , 2021, Yearbook of Medical Informatics.

[9]  S. Majumdar,et al.  A global panel database of pandemic policies (Oxford COVID-19 Government Response Tracker) , 2021, Nature Human Behaviour.

[10]  G. Lip,et al.  Associations between COVID-19 and 30-day thromboembolic events and mortality in people with dementia receiving antipsychotic medications , 2021, Pharmacological Research.

[11]  C. Chew‐Graham,et al.  Effects of the COVID-19 pandemic on primary care-recorded mental illness and self-harm episodes in the UK: a population-based cohort study , 2021, The Lancet. Public health.

[12]  L. Schneider,et al.  Antipsychotic prescribing to people with dementia during COVID-19 , 2020, The Lancet Neurology.

[13]  R. Allegri,et al.  COVID-19 Epidemic in Argentina: Worsening of Behavioral Symptoms in Elderly Subjects With Dementia Living in the Community , 2020, Frontiers in Psychiatry.

[14]  Naaheed Mukadam,et al.  Dementia prevention, intervention, and care: 2020 report of the Lancet Commission , 2020, The Lancet.

[15]  Andrew K. Przybylski,et al.  Multidisciplinary research priorities for the COVID-19 pandemic: a call for action for mental health science , 2020, The Lancet Psychiatry.

[16]  B. Pfefferbaum,et al.  Mental Health and the Covid-19 Pandemic. , 2020, The New England journal of medicine.

[17]  José Luis Molinuevo,et al.  Dementia care during COVID-19 , 2020, The Lancet.

[18]  J. O'Brien,et al.  Dementia: assessment, management and support: summary of updated NICE guidance , 2018, British Medical Journal.

[19]  A. Gasparrini,et al.  Interrupted time series regression for the evaluation of public health interventions: a tutorial , 2016, International journal of epidemiology.

[20]  G. Waldemar,et al.  Psychotropic Polypharmacy in Patients with Dementia: Prevalence and Predictors. , 2017, Journal of Alzheimer's disease : JAD.

[21]  C. Sudlow,et al.  Comparison of dementia recorded in routinely collected hospital admission data in England with dementia recorded in primary care , 2016, Emerging Themes in Epidemiology.

[22]  Rae Woong Park,et al.  Characterizing treatment pathways at scale using the OHDSI network , 2016, Proceedings of the National Academy of Sciences.

[23]  B. Sarfati,et al.  Validity And Limitations Of The Longitudinal Patient Database France For Use In Pharmacoepidemiological And Pharmacoeconomics Studies , 2015 .

[24]  Yu-Chuan Li,et al.  Observational Health Data Sciences and Informatics (OHDSI): Opportunities for Observational Researchers , 2015, MedInfo.

[25]  L. Schneider,et al.  Risk of mortality among individual antipsychotics in patients with dementia. , 2012, The American journal of psychiatry.

[26]  Truls Østbye,et al.  The accuracy of Medicare claims as an epidemiological tool: the case of dementia revisited. , 2009, Journal of Alzheimer's disease : JAD.